1 patient, T2 since mid-30s and now 59, had kidney transplant 2017 after end-stage diabetic nephropathy and fucked glucose control since 2019. The successful cells were endoderm stem cells from him cultivated by mice they injected with his PBMCs that they then made diabetic. So not from cadavers (except mouse cadaver i guess), which is the actual new part here. Intrahepatic implant, and cells from unrelated donor failed that were embedded at the same time. His personalised mouse-donor cells worked well enough to take him off insulin 3 months later.
1 patient, T2 since mid-30s and now 59, had kidney transplant 2017 after end-stage diabetic nephropathy and fucked glucose control since 2019. The successful cells were endoderm stem cells from him cultivated by mice they injected with his PBMCs that they then made diabetic. So not from cadavers (except mouse cadaver i guess), which is the actual new part here. Intrahepatic implant, and cells from unrelated donor failed that were embedded at the same time. His personalised mouse-donor cells worked well enough to take him off insulin 3 months later.
Wu, J., Li, T., Guo, M. et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov 10, 45 (2024).
It’s good news, but you’re entirely correct that the article missed the point entirely. Thanks for the crash course in islet cell therapy!